Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BUR
|
|||
| Former ID |
DCL000276
|
|||
| Drug Name |
ICA-17043
|
|||
| Synonyms |
Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215; Senicapoc
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Constitutional neutropenia [ICD-11: 4B00.0] | Discontinued in Phase 2 | [2], [3] | ||
| Company |
Icagen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H15F2NO
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
|
|||
| InChI |
1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
|
|||
| InChIKey |
SCTZUZTYRMOMKT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 289656-45-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9372859, 12015469, 14923962, 30420060, 47208291, 50074299, 57399777, 75535754, 85175958, 103108020, 103578829, 113461422, 117509693, 125674058, 126671456, 131311315, 134213427, 134338933, 134339678, 134345492, 135134888, 135650366, 137009025, 142477290, 143497061, 152237468, 152258814, 160647665, 160828321, 160850492, 162206457, 162223735, 162830809, 163390718, 164834159, 165237973, 186007028, 188932632, 198956389, 201501158, 204417860, 223395580, 223554883, 223666966, 224115686, 227654718, 247638311, 252214210
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel (KCN) | Target Info | Inhibitor | [4] |
| Calcium-activated potassium channel KCa3.1 (KCNN4) | Target Info | Modulator | [5] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2331). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013404) | |||
| REF 4 | Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. | |||
| REF 5 | Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.